Heterosexual transmission of HIV is the primary route in women, who now account for 50% of those infected. In the absence of an effective vaccine, other modes of prevention are needed. A safe and effective topical microbicide will allow women and men to play a more direct role in their own protection. As with therapeutic approaches to HIV, a topical microbicide that combines compounds with differing modes of action will have an advantage in blocking the complex interactions that occur in the mucosa at the time of transmission. Many women at risk who will use the compounds will not know their HIV status. Therefore, a microbicide approach must consider the impact of exposure of infected women to the compound and therefore topicals that do not represent major therapeutic antiretrovirals might be an advantage. Given the evidence that HSV enhances HIV transmission, agents that also impact on other STI will have an added benefit. This approach must be safe and not interfere with natural barriers to infection. The approach to the advancement of candidate microbicides proposed in this program takes into account each of these issues. We are proposing to advance the development of the novel compound SAMMA to formulated product that will include an acid buffer to combine the entry inhibitory activity of SAMMA with the direct effects of an acid pH on the virus. We will also explore the potential of other compounds such as novel persulfated molecular umbrellas (pmu) as well as cdk inhibitors. Both classes of compounds have activity against HIV and HSV. Each of these approaches will be carefully studied focusing not only on advancing candidate compounds but broadening our understanding of the interaction between critical host defenses and topical microbicides. Carefully planned pilot clinical evaluation of compounds already in clinical trials (cellulose sulfate, acidform and tenofovir) as well as the proposed formulated SAMMA will focus on the effects of these compounds on innate immunity as well as the development of surrogate markers for efficacy.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI069551-05
Application #
7395003
Study Section
Special Emphasis Panel (ZRG1-AARR-A (50))
Program Officer
Turpin, Jim A
Project Start
2005-09-01
Project End
2010-02-28
Budget Start
2008-03-01
Budget End
2009-02-28
Support Year
5
Fiscal Year
2008
Total Cost
$429,277
Indirect Cost
Name
Albert Einstein College of Medicine
Department
Type
DUNS #
110521739
City
Bronx
State
NY
Country
United States
Zip Code
10461
Keller, Marla J; Carpenter, Colleen A; Lo, Yungtai et al. (2012) Phase I randomized safety study of twice daily dosing of acidform vaginal gel: candidate antimicrobial contraceptive. PLoS One 7:e46901
Keller, Marla J; Madan, Rebecca P; Torres, N Merna et al. (2011) A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. PLoS One 6:e16475
Anton, Peter; Herold, Betsy C (2011) HIV transmission: time for translational studies to bridge the gap. Sci Transl Med 3:77ps11
Herold, Betsy C; Mesquita, Pedro M; Madan, Rebecca P et al. (2011) Female genital tract secretions and semen impact the development of microbicides for the prevention of HIV and other sexually transmitted infections. Am J Reprod Immunol 65:325-33
Verma, Natasha A; Lee, Anna C; Herold, Betsy C et al. (2011) Topical prophylaxis for HIV prevention in women: becoming a reality. Curr HIV/AIDS Rep 8:104-13
Wilson, Sarah S; Cheshenko, Natalia; Fakioglu, Esra et al. (2009) Susceptibility to genital herpes as a biomarker predictive of increased HIV risk: expansion of a murine model of microbicide safety. Antivir Ther 14:1113-24
Madan, Rebecca Pellett; Keller, Marla J; Herold, Betsy C (2006) Prioritizing prevention of HIV and sexually transmitted infections: first-generation vaginal microbicides. Curr Opin Infect Dis 19:49-54
MasCasullo, Veronica; Fam, Ehsan; Keller, Marla J et al. (2005) Role of mucosal immunity in preventing genital herpes infection. Viral Immunol 18:595-606